{"id":"W2404692795","doi":"10.1200/jco.2015.65.7171","title":"Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Eli Lilly and Company","keywords":"Medicine; Internal medicine; Hazard ratio; Placebo; Oncology; International Prognostic Index; Rituximab; Clinical endpoint; Diffuse large B-cell lymphoma; Gastroenterology; Cyclophosphamide; Maintenance therapy; Cumulative incidence; Surgery; Lymphoma; Randomized controlled trial; Chemotherapy; Transplantation; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00260894,0.002065342,0.003684583,0.0004733013,0.0005030773,0.001265382,0.001081043,0.002239572,0.006646179],"category_scores_gemma":[0.002467076,0.000797066,0.001657528,0.0003927493,0.001637279,0.001208972,0.000417759,0.003081616,0.001087434],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007689591,"about_ca_system_score_gemma":0.001444408,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007866275,"about_ca_topic_score_gemma":0.001901464,"domain_scores_codex":[0.9990295,0.0006105057,0.00005283446,0.0001523053,0.0000477012,0.0001071025],"domain_scores_gemma":[0.9986598,0.0004375757,0.0003223368,0.0001120763,0.00008928021,0.0003788145],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9876138,0.003903472,0.0002030797,0.0002659704,0.0003435486,0.00001536429,0.00002287491,0.0001805234,0.001446432,0.00005988511,0.0002894975,0.005655557],"study_design_scores_gemma":[0.9734072,0.02566077,0.0002864948,0.00001209336,0.0001094113,0.000009100027,0.000006559118,0.0001821304,0.0001339293,0.00005520944,0.0001327105,0.00000441674],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.981202,0.004921234,0.001337394,0.001191462,0.001362459,0.006797649,0.001099941,0.0002260164,0.001861787],"genre_scores_gemma":[0.9813508,0.00248227,0.002375544,0.001547132,0.0007008459,0.007042411,0.0007987875,0.00003019026,0.003672052],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006646179,"threshold_uncertainty_score":0.02223372,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08525202088888015,"score_gpt":0.4264275746891908,"score_spread":0.3411755538003107,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}